Parole chiave di "Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes."

Label

• Parole chiave di "Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes." (literal)
• Keywords of "Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes." (literal)

Insieme di parole chiave di

• Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes. (Articolo in rivista) (Prodotto della ricerca)

Ha membro

• Postprandial glucagon (Parola chiave)
• Postprandial insulin (Parola chiave)
• GLP-1 analog pancreatic function (Parola chiave)
• Mixed-meal tolerance test (Parola chiave)
• Postprandial glucose (Parola chiave)

Incoming links:

Insieme di parole chiave

• Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes. (Articolo in rivista) (Prodotto della ricerca)

Membro di

• GLP-1 analog pancreatic function (Parola chiave)
• Mixed-meal tolerance test (Parola chiave)
• Postprandial glucose (Parola chiave)
• Postprandial insulin (Parola chiave)
• Postprandial glucagon (Parola chiave)